Your browser doesn't support javascript.
loading
Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
Baresic, Marko; Reihl, Mirna; Habek, Mario; Vukojevic, Nenad; Anic, Branimir.
Afiliação
  • Baresic M; Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
  • Reihl M; Division of Physical Medicine, Rehabilitation and Rheumatology, Vukovar General Hospital, Zupanijska 35, 32000, Vukovar, Croatia. mirna.reihl@gmail.com.
  • Habek M; Department of Neurology, Referral Center for Autonomic Nervous System Disorders, School of Medicine, University of Zagreb, University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
  • Vukojevic N; Department of Ophthalmology, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
  • Anic B; Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Rheumatol Int ; 38(7): 1301-1306, 2018 07.
Article em En | MEDLINE | ID: mdl-29777341
ABSTRACT
Behçet's disease is a chronic inflammatory condition of unknown origin characterized by multiple organ involvement. The most common symptoms of Behçet's disease are recurrent oral and/or genital ulcerations in combination with symptoms affecting eyes, skin, central and peripheral nervous system, blood vessels and gastrointestinal tract. We present a 43-year-old female patient with the history of recurrent episodes of genital and oral ulcerations, elevated acute phase reactants and skin lesions. The diagnosis of Behçet's disease has been delayed (for more than 10 years) and reached only after she developed neurological and ocular symptoms. Treatment with glucocorticoids and azathioprine was partially successful. High doses of glucocorticoids were needed to control the disease and cyclosporine A was nephrotoxic. Remission was reached after the introduction of infliximab (plus methotrexate) and glucocorticoids were stopped. In the recent years, infliximab has been accepted as a standard therapy for refractory cases of Behçet's disease (neurological, ocular or gastrointestinal). Our patient presented with refractory ocular and neurological symptoms and infliximab was effective for both manifestations. Long-term side-effects of glucocorticoids and other immunosuppressants can be avoided with TNF-α blockade. We emphasize the importance of a timely and accurate diagnosis and significance of excluding more common diseases in a work-up algorithm.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Behçet / Infliximab Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Behçet / Infliximab Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article